We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Insmed (INSM) Q3 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that Insmed (INSM - Free Report) will announce quarterly loss of -$1.32 per share in its forthcoming report, representing a decline of 3.9% year over year. Revenues are projected to reach $114.65 million, increasing 22.7% from the same quarter last year.
The current level reflects a downward revision of 0.6% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Insmed metrics that are routinely monitored and predicted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Revenue- Japan' of $29.88 million. The estimate points to a change of +42.4% from the year-ago quarter.
The average prediction of analysts places 'Revenue- Europe and rest of world' at $7.24 million. The estimate suggests a change of +29.8% year over year.
The consensus among analysts is that 'Revenue- U.S.' will reach $72.72 million. The estimate indicates a year-over-year change of +8.8%.
Shares of Insmed have demonstrated returns of +14.8% over the past month compared to the Zacks S&P 500 composite's +3.8% change. With a Zacks Rank #3 (Hold), INSM is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gear Up for Insmed (INSM) Q3 Earnings: Wall Street Estimates for Key Metrics
Analysts on Wall Street project that Insmed (INSM - Free Report) will announce quarterly loss of -$1.32 per share in its forthcoming report, representing a decline of 3.9% year over year. Revenues are projected to reach $114.65 million, increasing 22.7% from the same quarter last year.
The current level reflects a downward revision of 0.6% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Insmed metrics that are routinely monitored and predicted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Revenue- Japan' of $29.88 million. The estimate points to a change of +42.4% from the year-ago quarter.
The average prediction of analysts places 'Revenue- Europe and rest of world' at $7.24 million. The estimate suggests a change of +29.8% year over year.
The consensus among analysts is that 'Revenue- U.S.' will reach $72.72 million. The estimate indicates a year-over-year change of +8.8%.
View all Key Company Metrics for Insmed here>>>Shares of Insmed have demonstrated returns of +14.8% over the past month compared to the Zacks S&P 500 composite's +3.8% change. With a Zacks Rank #3 (Hold), INSM is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .